Anti-Epileptic Drugs Market By Spectrum Type, By Drug and Geography – Opportunities & Forecast 2027 | Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd. And Alkem Labs
Anti-Epileptic Drugs |
Antiepileptic drugs (AEDs), often known as anticonvulsants or antiseizure medicines, are used to treat epileptic seizures symptomatically. Epileptic seizures are characterised by recurrent occurrences and are caused by nerve cells sending incorrect signals to the brain. Antiepileptic medications are also used to treat bipolar disorders and neuropathic pain and function as mood stabilisers. The market for antiepileptics has been fueled by new medication approvals in recent years.
The adoption of alternative therapy for children with epilepsy is likely to slow the growth of the global anti-epileptic drugs market over the forecast period. In addition to AEDs, complementary and alternative medicine (CAM) such as the ketogenic diet, modified Atkins diet (MAD), and low glycemic index therapy (LGIT) are commonly used to treat epilepsy in children. According to Clinical Nutrition Research (a research study conducted to examine the consumption of nutritional supplements used in various treatments), around 30% of children suffering from uncontrolled epileptic seizures were untreated worldwide in 2016, and a ketogenic diet (KD) could be used as an alternative medical treatment for these children. These factors are expected to restrain the global anti-epileptic drugs market growth.
Market Segmentation:
By Generation:
By Route of Administration:
By Distribution Channel:
Over the projection period, the market is likely to rise due to an increase in the number of inorganic growth tactics such as collaborations by prominent companies. In February 2019, for example, SK Biopharmaceuticals and Arvelle Therapeutics agreed to collaborate on the development and commercialization of SK Biopharmaceuticals' Cenobamate in Europe. Cenobamate is an anti-epileptic medication used to treat people with partial-onset seizures.
- First Generation
- Second Generation
- Third Generation
By Route of Administration:
- Oral
- Intravenous
By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
Over the projection period, the market is likely to rise due to an increase in the number of inorganic growth tactics such as collaborations by prominent companies. In February 2019, for example, SK Biopharmaceuticals and Arvelle Therapeutics agreed to collaborate on the development and commercialization of SK Biopharmaceuticals' Cenobamate in Europe. Cenobamate is an anti-epileptic medication used to treat people with partial-onset seizures.
The major key players operating in the global anti-epileptic drugs market are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a, Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., and Bausch Health Companies Inc.
Comments
Post a Comment